Press Releases.
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 07, 2015- Advanced 'Clinical Map Initiative' with Positive Results on RG-101 and Selection of RG-125 as 3rd Clinical Candidate -
-
April 25, 2015-RG-101 Achieves Sustained HCV Viral Suppression with Favorable Safety and Tolerability-
-
April 09, 2015-Late-breaking data featured in oral presentation; three additional posters examining RG-101 pharmacokinetics, preclinical results to be presented-
-
April 07, 2015-Regulus Earns $2.5 Million Milestone Payment from AstraZeneca-
-
February 18, 2015- Achieved Key 2014 'Clinical Map Initiative' Goals to Advance microRNA Therapeutics Pipeline -
-
February 09, 2015-Extended Follow-Up Shows 4/14 Patients Treated with a Single SC Dose of 2 mg/kg of RG-101 are Target Not Detected at Day 85 -
-
January 08, 2015Accelerates RG-101 for HCV with Dual-Track Clinical Development Strategy; Top-Line, Single Dose, 4 mg/kg Results as Well as 2mg/kg Extended Follow Up Results from Ongoing Study to be Reported in Early February 2015
-
November 15, 2014- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome -
-
November 06, 2014
-
November 05, 2014- Demonstrated Human Proof-of-Concept; 'Clinical Map Initiative' Updated -
-
October 28, 2014
-
October 27, 2014
-
October 22, 2014- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform -
-
October 14, 2014-New Preclinical Results Increase Mechanistic Understanding of Targeting miR-103/107 for Metabolic Disorders and miR-21 for Renal Dysfunction in Alport Syndrome Patients-